Disclaimer

Please note that you are now entering a website directly or indirectly maintained by a third party (the "External Site") and that you do so at your own risk.

Please note that you are now entering a website directly or indirectly maintained by a third party (the "External Site") and that you do so at your own risk.

By clicking “Accept” you acknowledge and agree that neither ITGR nor third party provider Virtua Research, Inc. (“Virtua) is responsible, or accepts or assumes any responsibility or liability whatsoever for, the content, the data or the technical operation of the Linked Site. Further, by entering the External Site, you also acknowledge and agree that you completely and irrevocably waive any and all rights and claims against ITGR and Virtua and further acknowledge and agree that in no event shall ITGR or Virtua, its officers, employees, directors and agents be liable for any (i) indirect, consequential, incidental, special, compensatory or punitive damages, (ii) damages for loss of income, loss of business profits, business interruption, loss of data or business information, loss of or damage to property, (iii) claims of third parties, or (iv) other pecuniary loss, arising out of or related to this disclaimer or the External Site

By entering the External Site, you further acknowledge and agree that the disclaimer of warranties and limitations of liability set out in this disclaimer shall apply regardless of the causes, circumstances or form of action giving rise to the loss, damage, claim or liability, even if such loss, damage, claim or liability is based upon breach of contract (including, without limitation, a claim of fundamental breach or breach of a fundamental term), tort (including, without limitation, negligence), strict liability or any other legal or equitable theory, and even if ITGR and Virtua are advised of the possibility of the loss, damage, claim or liability. The waiver and release specifically includes, without limitation, any and all rights and claims pertaining to the processing of personal data, including but not limited to any rights under any applicable data protection statute(s).

If in any jurisdiction, any part of this disclaimer is held to be unenforceable by a court of competent jurisdiction, such part of this disclaimer shall be restricted or eliminated to the minimum extent and the remaining disclaimer shall otherwise remain in full force and effect.

Please note the information presented is deemed representative at the time of its original release. Changes in historical information may occur due to adjustments in accounting and reporting standards & procedures.

Non-GAAP Information

In addition to disclosing results determined in accordance with GAAP, ITGR may also disclose certain non-GAAP and pro forma non-GAAP results of operations, including certain ratios, operational and miscellaneous data, as well as net income, diluted earnings per share, operating expenses, and operating income that make certain adjustments or exclude certain charges and gains that are outlined in the schedules included in this website. Management believes that this non-GAAP and pro forma non-GAAP information provides investors with additional information to assess ITGR operating performance by making certain adjustments or excluding costs or gains and assists investors in comparing our operating performance to prior periods. Management uses this non-GAAP and pro forma non-GAAP information, along with GAAP information, in evaluating its historical operating performance. ITGR and Virtua also take no responsibility for third party pricing data provided for informational purposes and certain ratio results formulated from the provided third party pricing data.

The non-GAAP information is not prepared in accordance with GAAP and may not be comparable to non-GAAP information used by other companies. The non-GAAP information should not be viewed as a substitute for, or superior to, other data prepared in accordance with GAAP.

Integer Wins Long-Term Supply Agreement with Neuros Medical

December 06 2017

FRISCO, Texas and WILLOUGHBY HILLS, Ohio, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading medical device outsource (MDO) manufacturer, today announced that its subsidiary, Centro de Construccion de Cardioestimuladores del Uruguay S.A. (CCC), has signed a ten-year supply agreement with Neuros Medical, Inc. (Neuros). Under the new agreement, CCC will be the sole supplier of key “Products” for Neuros’ Altius® System. The Products include the implantable generator and related external devices (Clinician Programming Wand, Patient Controller, and Charger).

Neuros Medical Logo


Neuros is currently conducting its pivotal IDE clinical study to evaluate its patented Altius® System High Frequency Nerve Block technology for the management of post-amputation pain (including post-amputation pain, phantom limb-pain, residual limb pain, and stump pain).

“We are honored to be awarded this long-term supply agreement with Neuros, a company that shares our vision to enhance the lives of patients worldwide through life-changing technology,” said Tony Gonzalez, president of Integer’s Cardiac Rhythm Management and Neuromodulation product line. “This agreement highlights Integer’s breadth of capabilities to support customers with design, development and manufacturing of advanced technologies and systems. By leveraging our fully customizable platforms and our systems expertise, we will help Neuros bring its therapy to market quickly and cost-effectively, while maintaining the utmost quality and reliability. We look forward to continuing our relationship with the Neuros team as they progress through their current clinical study and beyond.”

Tom Wilder, Neuros Medical’s president and chief executive officer, said, “We are excited to have Integer as a strategic partner and supplier in our long-term plans to utilize our High Frequency Nerve Block technology to address unmet medical needs involving chronic nerve pain. This includes continued enrollment in and completion of our pivotal IDE clinical study to investigate the use of the Altius System for treatment of post-amputation pain.”

About Integer™
Integer Holdings Corporation (NYSE:ITGR) is one of the largest medical device outsource (MDO) manufacturers in the world serving the cardiac, neuromodulation, orthopedics, vascular, advanced surgical and portable medical markets. The company provides innovative, high-quality technologies and manufacturing to Medical Device OEM’s to enhance the lives of patients worldwide. In addition, it develops batteries for high-end niche applications in energy, military, and environmental markets. The company's brands include Greatbatch™ Medical, Lake Region Medical and Electrochem. Additional information is available at www.integer.net.

About Neuros Medical, Inc.
Neuros Medical, Inc. is a neuromodulation company that is focused on developing proprietary therapies for unmet needs to patients worldwide. The Company’s patented platform technology, the Altius® High Frequency Electrical Nerve Block, is focused on the elimination of chronic pain in a variety of conditions, including amputation pain, post-surgical pain, migraine, and trigeminal neuralgia. The Neuros Altius System consists of an implantable generator with an integrated rechargeable battery, cuff electrode, and external devices (Clinician Programming Wand, Patient Controller and Charger).

CAUTION -- Investigational device. Limited by Federal (or United States) law to investigational use.

Neuros Contacts
Thomas C. Wilder
twilder@neurosmedical.com
440.951.2565

Integer Contacts
Investor Relations
Amy Wakeham
IR@integer.net
214.618.4978

Media Relations
Kelly Butler
kelly.butler@integer.net
214.618.4216

Primary Logo

Source: Integer Holdings Corporation